Korean biopharmaceutical firms Samsung Biologics, Celltrion, and Lotte Biologics will showcase their advancements at the J.P. Morgan Healthcare Conference.
Samsung Biologics will focus on scaling up its production and research sites for the coming decades with an aim of venturing into new drug formats like vaccines and developing new medication beyond its core biosimilar business.
Korea JoongAng Daily Sitemap
